Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: Semma Raises $114m As VC Funding Keeps Up Brisk Pace

Executive Summary

Semma closed a $114m Series B round to fund development of insulin-producing cells. Also, Tesaro and Catalyst are among recent public company financings, while Otonomy shifted gears, laying off sales staff.

Advertisement

Related Content

Oyster Point Looks To Compete In Dry Eye With Nasal Spray Therapeutic
resTORbio's Age-Related RTI Program Picks Up Further Funding
Phase III Data Support Catalyst's NDA Resubmission For Firdapse
Tesaro Shakes Up EU PARP Market With Zejula Launches
Finance Watch: NDA-Ready Impact Gets Commitment For Another $90m
Finance Watch: Genocea, Mateon Shift Strategies, Cut Jobs To Preserve Cash
Horama's Gene Therapies For Retinal Diseases: Fast Followers?
Cystic Fibrosis: Successes, Opportunities And Challenges
Former Biogen R&D Chief Surfaces With Exosome-Focused Startup
Diabetes start-up brings in cash and a partner

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099990

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel